ARGX-117 is a Monoclonal Antibody owned by Argenx, and is involved in 5 clinical trials, of which 2 were completed, 1 is ongoing, and 2 are planned.

ARGX-117 is a complement C2 inhibitor. It blocks complement-mediated cytotoxicity of human cells sensitized with anti-HLA antibodies. The therapeutic candidate proves to be effective in the prevention of ischemia reperfusion damage by checking the underlying cause.

The revenue for ARGX-117 is expected to reach a total of $52m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the ARGX-117 NPV Report.

ARGX-117 was originated by Argenx and Broteio Pharma and is currently owned by Argenx.

ARGX-117 Overview

ARGX-117 (PRO-02) is under development for the prevention of ischemia-reperfusion damage and antibody-mediated diseases like autoimmune hemolytic anemia (AIHA), antibody-mediated rejection (AMR) following organ transplantation. It is administered through the intravenous route. It acts by targeting complement C2 cascade. The therapeutic candidate is a monoclonal antibody equipped with Argenx’s proprietary Fc engineering technology NHance. It is also under development for the treatment of multifocal motor neuropathy and kidney diseases. It was also under development for acute respiratory distress syndrome (ARDS) in COVID-19 patients.

Argenx Overview

Argenx is an immunology company that focuses on the development of human antibodies. The company is primarily developing products for autoimmune diseases. Its key product includes VYVGART, a neonatal Fc receptor blocker, which is used to treat generalized myasthenia gravis in adults which are anti-acetylcholine receptor (AChR) antibody positive. The company’s pipeline products include Efgartigimod, ARGX-117, Cusatuzumab, ARGX-118, ARGX-119 and ARGX-120. Argenx in partnership with Leo Pharma, AgoMab, AbbVie and Staten has been licensed to develop products such as ARGX-112, ARGX-114 and ARGX-115. The company develops antibodies using its proprietary technology platforms such as NHance, simple antibody technology, and others. It operates offices in the Netherlands, the United States, Japan, Switzerland and Belgium. Argenx is headquartered in Breda, the Netherlands.

The company reported revenues of (US Dollars) US$497.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$41.2 million in FY2020. The operating loss of the company was US$348.8 million in FY2021, compared to an operating loss of US$477.6 million in FY2020. The net loss of the company was US$408.3 million in FY2021, compared to a net loss of US$608.5 million in FY2020. The company reported revenues of US$138 million for the third quarter ended September 2022, an increase of 39.9% over the previous quarter.

Quick View – ARGX-117

Report Segments
  • Innovator
Drug Name
  • ARGX-117
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Genito Urinary System And Sex Hormones
  • Hematological Disorders
  • Immunology
  • Infectious Disease
Key Companies
  • Sponsor Company: Argenx
  • Originator: Argenx and Broteio Pharma
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.